Cover Image

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant <i>Enterobacterales</i> Isolates from South Korea

Ceftazidime-avibactam (CAZ-AVI) and aztreonam-avibactam (AZT-AVI) are novel antibiotic combinations active against multidrug-resistant Gram-negative pathogens. This study aimed to evaluate their in vitro activities and inoculum effects in carbapenem-resistant <i>Enterobacterales</i> (CRE...

Full description

Saved in:

Bibliographic Details
Main Authors:	Taeeun Kim (Author), Seung Cheol Lee (Author), Moonsuk Bae (Author), Heungsup Sung (Author), Mi-Na Kim (Author), Jiwon Jung (Author), Min Jae Kim (Author), Sung-Han Kim (Author), Sang-Oh Lee (Author), Sang-Ho Choi (Author), Yang Soo Kim (Author), Yong Pil Chong (Author)
Format:	Book
Published:	MDPI AG, 2020-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
by: Moonsuk Bae, et al.
Published: (2021)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
by: Wei Yu, et al.
Published: (2021)

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope
by: Rawan Taha, et al.
Published: (2023)

Correction: Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope
by: Rawan Taha, et al.
Published: (2023)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against <i>Klebsiella pneumoniae</i> by MALDI-TOF MS
by: Camila Mörschbächer Wilhelm, et al.
Published: (2023)

In Vitro Activity of Aztreonam-avibactam and Ceftazidime-avibactam against Pseudomonas aeruginosa Collected in a Global Surveillance Program in the Africa/Middle East, 2014-2017
by: I Morrissey, et al.
Published: (2020)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
by: Rémy A. Bonnin, et al.
Published: (2023)

Synergistic Combination of Aztreonam and Ceftazidime-Avibactam-A Promising Defense Strategy against OXA-48 + NDM <i>Klebsiella pneumoniae</i> in Romania
by: Ioana Miriana Cismaru, et al.
Published: (2024)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023)

Meropenem plus Ertapenem and Ceftazidime-Avibactam plus Aztreonam for the Treatment of Ventilator Associated Pneumonia Caused by Pan-Drug Resistant <i>Klebsiella pneumonia</i>
by: Konstantinos Mantzarlis, et al.
Published: (2024)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
by: Marco Fiore, et al.
Published: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
by: George L. Daikos, et al.
Published: (2021)

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria
by: S. V. Nedogoda, et al.
Published: (2019)

Bloodstream Infections Due to Wild-Type <i>Pseudomonas aeruginosa</i>: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes
by: Carlo Pallotto, et al.
Published: (2024)

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
by: Karoline Knudsen List, et al.
Published: (2022)

Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022)

In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
by: Tobias Manuel Appel, et al.
Published: (2020)

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant <em>Enterobacterales</em>
by: Antonio Vena, et al.
Published: (2020)

The Rapid Emergence of Ceftazidime-Avibactam Resistance Mediated by KPC Variants in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Zhejiang Province, China
by: Congcong Liu, et al.
Published: (2022)

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter
by: Shikai Wu, et al.
Published: (2023)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by: Andrea Marino, et al.
Published: (2023)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Ceftazidime-avibactam induced renal disorders: past and present
by: Yanrong Shi, et al.
Published: (2024)

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections-In Vitro Susceptibility Testing
by: Małgorzata Brauncajs, et al.
Published: (2024)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
by: Cécile Emeraud, et al.
Published: (2023)

Ceftazidime-Avibactam Versus Polymyxin-Based Combination Therapies: A Study on 30-Day Mortality in Carbapenem-Resistant Enterobacterales Bloodstream Infections in an OXA-48-Endemic Region
by: Rıdvan Dumlu, et al.
Published: (2024)

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant <i>Klebsiella pneumoniae</i>: A Retrospective Case Series and Literature Review
by: Alessandra Belati, et al.
Published: (2022)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023)

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
by: Wenqiang Kong, et al.
Published: (2023)

Investigating the mechanism of ceftazidime-avibactam resistance in addition to the effect of vancomycin on antibacterial resistance in carbapenem-resistant Klebsiella pneumonia
by: Nour Sherri, et al.
Published: (2020)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023)

Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and <i>Pseudomonas aeruginosa</i> from Intensive Care Unit and Non-Intensive Care Unit Patients
by: Helio S. Sader, et al.
Published: (2024)

Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>
by: Anthony Sophonsri, et al.
Published: (2024)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022)

Ceftazidime-Avibactam Treatment for <i>Klebsiella pneumoniae</i> Bacteremia in Preterm Infants in NICU: A Clinical Experience
by: Andrea Marino, et al.
Published: (2023)

Therapeutic Drug Monitoring of Ceftazidime-Avibactam Concentrations in Carbapenem-Resistant K. pneumoniae-Infected Patients With Different Kidney Statuses
by: Xin-Qi Teng, et al.
Published: (2022)

Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children
by: Zhu L, et al.
Published: (2024)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016)